CEO of Tylenol Manufacturer Addresses Autism Concerns in Meeting with RFK Jr.

September 12, 2025 - 20:35

In a recent private meeting, the interim CEO and director of Kenvue, the company behind the popular pain reliever Tylenol, engaged in discussions with U.S. Health and Human Services Secretary Robert F. Kennedy Jr. The meeting aimed to address concerns regarding the potential association between the medication and autism. The CEO emphasized that scientific research has not established any clear link between the use of Tylenol and the development of autism spectrum disorders.

The dialogue comes amidst rising scrutiny and ongoing debates surrounding the safety of various medications during pregnancy and early childhood. The CEO's efforts appear to be focused on preventing the inclusion of Tylenol in a forthcoming report that could suggest a connection to autism, a point of contention that has garnered significant public interest and concern.

Both parties acknowledged the importance of continuing to review and analyze existing research to ensure public safety while addressing the anxieties of parents and caregivers.